Skip to main content
Dr. Nigel Key

September 19, 2022

BRC Investigators Publish Results of Randomized Trial of Anti-Fibrinolytic Therapy and Ancillary Laboratory Study in ‘Blood’ and ‘Blood Advances’

In the NIH-funded ‘American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)’ trial, UNC was one of 3 participating clinical centers to enroll patients with platelet transfusion-dependence due to therapy for hematologic malignancies. Between 2016 and 2020, 337 patients were randomized in a double blind fashion to tranexamic acid (TXA) or placebo. Ultimately, no benefit of …

photo of matthew karafin, smiling in a suit

July 26, 2022

Matt Karafin, MD is a Collaborating Investigator on a Recently Awarded Multi-Institution R21 Grant From the NIH-NHBLI

The focus of the grant is to investigate red blood cell alloimmunization risk using the REDS-III databases. Red blood cell (RBC) alloimmunization is a leading cause of morbidity and mortality in transfusion and pregnancy settings, resulting in hemolytic reactions and other adverse sequelae such as hemolytic disease of the fetus and newborn. Alloimmunization occurs in …